Filings
Finds words inside filing documents. Searching Solid Biosciences Inc.'s filings · 17 documents indexed.
7 documents · 7 matches
-
SLDB Solid Biosciences Inc. 10-Q 2025-05-15
Item 1A. Risk Factors.
weakness and myocarditis, in clinical trials of other gene therapy treatments for Duchenne that may be related to the type and location of the specific gene mutation causing the disease. One clinical trial sponsor reported a death, preceded by hypovolemia and cardiogenic shock1 match in this document -
SLDB Solid Biosciences Inc. 10-Q 2026-11-04
Item 1A. Risk Factors.
weakness, myocarditis, and acute liver injury, in clinical trials of other gene therapy treatments for Duchenne that may be related to the type and location of the specific gene mutation causing the disease. In another gene therapy treatment, there have been reports of AAV mediated1 match in this document -
SLDB Solid Biosciences Inc. 10-Q 2026-08-06
Item 1A. Risk Factors.
weakness, myocarditis, and acute liver injury, in clinical trials of other gene therapy treatments for Duchenne that may be related to the type and location of the specific gene mutation causing the disease. In another gene therapy treatment, there have been reports of AAV mediated1 match in this document -
SLDB Solid Biosciences Inc. 10-Q 2026-05-12
Item 1A. Risk Factors.
weakness, myocarditis, and acute liver injury, in clinical trials of other gene therapy treatments for Duchenne that may be related to the type and location of the specific gene mutation causing the disease. In another gene therapy treatment, there have been reports of AAV mediated1 match in this document -
SLDB Solid Biosciences Inc. 10-K 2026-03-19
Item 1A. Risk Factors.
weakness, myocarditis, and acute liver injury, in clinical trials of other gene therapy treatments for Duchenne that may be related to the type and location of the specific gene mutation causing the disease. In another gene therapy treatment, there have been reports of AAV mediated1 match in this document -
SLDB Solid Biosciences Inc. 10-Q 2025-11-03
Item 1A. Risk Factors.
weakness, myocarditis, and acute liver injury, in clinical trials of other gene therapy treatments for Duchenne that may be related to the type and location of the specific gene mutation causing the disease. In another gene therapy treatment, there have been reports of AAV mediated1 match in this document -
SLDB Solid Biosciences Inc. 10-Q 2025-08-12
Item 1A. Risk Factors.
weakness, myocarditis, and acute liver injury, in clinical trials of other gene therapy treatments for Duchenne that may be related to the type and location of the specific gene mutation causing the disease. In another gene therapy treatment, there have been reports of AAV mediated1 match in this document
Page 1 of 1 · 7 documents